Oral Lichen Planus Clinical Trial
Official title:
Efficacy of 200mg and 300mg Concentrates of Green Tea Polyphenols Using Buccal Tablets Versus Topical Application of Corticosteroids in Treatment of Patients With Symptomic Oral Lichen Planus Randomized Clinical Trial
Is topical application of green tea polyphenols buccal tablet more effective in treatment of patients with symptomatic oral lichen planus in comparison with topical application of corticosteroids and what is the most effective concentration of polyphenols
- Each patient was informed about the detailed procedure, and educated about benefits of
the treatment, the known side effects and follow-up appointments needed. After that,
each subject participating in the study signed an informed written consent form.
- Subjects were given freedom to leave the study at any time when they need to. Group A
(Experimental group) 200 mg green tea
Where patients in this group will receive a buccal tablet containing 200 mg of green tea
extract which adheres to the buccal mucosa slowly releasing the polyphenoles along around 8
hours 2 times aday for four weeks.
Preparation of buccal tablets : Mucoahesive buccal tablets is prepared by a direct
compression procedure. Various batches are prepared by varying the chitosan:drug ratio to
identify the most effective formulation. The mucoadhesive drug/polymer mixture is prepared by
homogeneous mixing of the drug with chitosan , secondary polymer, and D-mannitol, in a glass
mortar for 15 min. Then, Mg stearate will be added and mixed for 5 min .The mixture is
compressed using a tablet machine (Type EK: O.Erweka apparatus, Frankfurt, Germany) using
flat-tip punches and dies with 8-mm-diameter. Each tablet weighed 212 mg with a thickness of
3.1 mm.( Darwish and Elmeshad,2009)
Group B (Experimental group) 300 mg green tea
Where patients in this group will receive a buccal tablet containing 300 mg of green tea
extract which adheres to the buccal mucosa slowly releasing the polyphenoles along around 8
hours 2 times aday for four weeks.
Group C (Control group) corticosteroid group:
Where patients are treated with topical corticosteroids 1 mg/g Triamcinolone acetonide
(Kenacort-A orabase 20 G Pomad: Deva dermatological product,Turkey) applied topically 4 times
a day i.e. following each meal and at bed time for four weeks .
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05997173 -
The Regulatory Role of Immune Response in Oral Lichen Planus
|
||
| Completed |
NCT02443311 -
Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus
|
Phase 4 | |
| Completed |
NCT00484250 -
Study of Metronidazole and Doxycycline to Treat Oral Lichen Planus and to Compare Their Efficacy With Each Other
|
Phase 2 | |
| Completed |
NCT03682562 -
Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
|
||
| Not yet recruiting |
NCT06428630 -
Systemic Absorption of Dexamethasone Oral Rinse in Patients With Oral Lichen Planus
|
Early Phase 1 | |
| Completed |
NCT04193748 -
Evaluation of Topical Pomegranate Extracts in Management of Oral Lichen Planus (A Randomized Clinical Trial)
|
Phase 4 | |
| Completed |
NCT04153266 -
Oral Epithelial Dysplasia Informational Needs Questionnaire
|
||
| Recruiting |
NCT06135805 -
Impact of Fluocinonide 0,05% in Oral Lichen Planus
|
N/A | |
| Completed |
NCT04289233 -
Molecular & Cellular Characterisation of Oral Lichen Planus
|
||
| Completed |
NCT04293718 -
Acquired Chronic Erosive Gingivitis: Clinical Relevance of Papillary Gingival Biopsy
|
||
| Completed |
NCT00525421 -
A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus
|
Phase 2 | |
| Not yet recruiting |
NCT04091698 -
Clinical and Biochemical Assessment of the Effect of Topical Use of Coenzyme Q10 Versus Topical Corticosteroid in Management of Symptomatic Oral Lichen Planus: Randomized Controlled Clinical Trial
|
Phase 1 | |
| Completed |
NCT03386643 -
Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus
|
Phase 2 | |
| Withdrawn |
NCT03836885 -
Apremilast - Oral Lichen Planus Trial
|
Phase 2 | |
| Completed |
NCT05730855 -
Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions
|
||
| Completed |
NCT03257228 -
The Association Between Diabetes Mellitus, Oral Lichen Planus and Insulin-like Growth Factors 1 and 2 (IGF1 and IGF2)
|
N/A | |
| Recruiting |
NCT03026478 -
Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus
|
Phase 2 | |
| Completed |
NCT02834520 -
Expression of miRNa-138 and Cyclin D1 in Oral Mucosa of Patients With Oral Lichen Planus
|
N/A | |
| Completed |
NCT02858297 -
Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus
|
Phase 4 | |
| Completed |
NCT02106468 -
The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus
|
Phase 2 |